The Hiring Arithmetic: Three Roles SNMMI 2026 Told You Will Be Near-Impossible to Fill
The most important announcement at SNMMI 2026 was not a drug. It was a training programme. Here is what that means for radiopharma hiring over the next three years.
Byron Fitzgerald
Founder, ProGen Search
The signal nobody covered
SNMMI 2026 in Los Angeles produced headline-grabbing science. Novartis's Pluvicto data in earlier-stage prostate cancer. The Curium approach for Lantheus. Actinium-225 supply announcements from TerraPower and Niowave.
The announcement that mattered most for anyone running a radiopharma operation barely made the trade press.
SNMMI's Technologist Section launched a hands-on theranostics certificate programme. The society also ran its first dedicated Regulatory Boot Camp.
When a professional society starts building emergency credentialing infrastructure, it is sending a specific signal: the workforce cannot deliver what the science is promising.
Premium intelligenceLooking for our flagship intelligence? See the premium reports →
The backfill cascade
Every new radiopharma facility creates more hiring demand than appears on the org chart.
Novartis is building five US radioligand therapy manufacturing sites. Three are operational and expanding. Two more are planned.
The arithmetic:
- Site Director promoted from Indianapolis to lead the new Texas facility
- Indianapolis now needs a Site Director
- VP Quality steps up to fill the gap
- VP Quality seat opens
- Director moves up
- Director seat opens
One new facility does not create five leadership searches. It creates fifteen.
Now multiply across the sector:
- TerraPower broke ground on a $450M Ac-225 facility in Philadelphia
- Niowave is building a $75M second Ac-225 plant in Michigan
- Cardinal Health is expanding its radiopharmacy network
- NorthStar is scaling isotope production
- Nucleus RadioPharma raised OrbiMed financing for CDMO expansion
All expanding in the same 18-month window. All drawing from the same pool of qualified candidates.
On top of this, multiple alpha-emitter programmes are heading toward registrational trials simultaneously. Novartis has two Phase 3 trials planned for 225Ac-PSMA-617 (PSMAcTION and AcTFirst). Actinium, Convergent, Molecular Partners, and Perspective Therapeutics all have Ac-225 or Pb-212 programmes advancing. Each trial site needs qualified radiochemists, radiation safety officers, and nuclear medicine physicians who can manage novel isotopes and short half-life logistics.
The training pipeline for these specialists does not exist at the scale the market now demands.
Three roles about to become near-impossible to fill
1. Alpha-qualified radiochemists
This is the most acute bottleneck.
Alpha-emitting isotopes (Ac-225, Pb-212) require different handling, shielding, and waste management protocols than the beta-emitting Lu-177 and Y-90 that most radiochemists have trained on:
- Decay chains are more complex
- Radiological hazard profiles are different
- NRC oversight adds a second regulatory layer that standard pharma manufacturing does not encounter
Operator dose limits compound the problem. NRC regulations cap extremity exposure at 500 mSv per year. At commercial therapy volumes (tens of thousands of patient doses annually), this means rotating radiochemistry staff three deep to stay within limits.
The qualified pool is small. Everyone in the sector is hiring from it simultaneously. Compensation is escalating. And the training time to produce a new alpha-qualified radiochemist is measured in years, not months.
We run searches in this space regularly. The market is already tight. It is about to get dramatically tighter.
2. Dosimetry and AI leads
SNMMI 2026 showcased a clear shift in how dosimetry is viewed by the clinical community.
ITM's COMPETE data demonstrated single-timepoint dosimetry for 177Lu-edotreotide in GEP-NETs, using population-based modelling to estimate absorbed doses from a single imaging session rather than the traditional multi-day scanning protocol. Separately, multiple abstracts featured machine-learning pre-therapy dose prediction from PET radiomics.
These are transitioning from academic research tools to hospital procurement requirements.
Practical dosimetry is essential for scaling personalised radioligand therapy. It determines whether a hospital can treat patients efficiently enough to make the service economically viable. Software that compresses a multi-day dosimetry workflow into a single scan effectively triples a hospital's theranostic capacity.
The people who can validate these tools in a clinical workflow, integrate them with hospital IT systems, and operationalise them across multiple sites represent a new professional category. It sits at the intersection of medical physics, software engineering, and clinical operations.
The role barely exists as a defined hire today. Within three years, it will be a hard requirement for any hospital or CDMO offering theranostic services at scale.
3. Hospital infrastructure leaders
Buried in the SNMMI programme was a presentation from Kanazawa University Hospital on low-cost activated carbon absorbents for radioactive wastewater. The data showed greater than 90% removal of Lu-177 and I-131 from hospital wastewater under certain conditions.
This sounds like a niche environmental engineering topic. It is not.
As radioligand therapy volumes scale, patient excretion pushes hospitals toward municipal radioactive discharge limits. These limits are set by local regulatory authorities and are not easily adjusted. A hospital that breaches its discharge limits must either install filtration and holding systems or reduce patient throughput.
Managing this requires someone who understands:
- Radioactive waste compliance
- Shielded-bed scheduling
- Site licensing and NRC requirements
- Hospital facilities management
This role sits between nuclear medicine departments and hospital operations. Neither department currently owns it. Neither training pipeline produces it.
As radiopharma moves from a handful of academic centres to hundreds of community treatment sites, this will become one of the most important operational hires in the sector. Almost nobody is mapping it yet.
The timing problem
A VP Quality in radiopharma needs approximately 18 months in-seat before an FDA pre-approval inspection. That time is required to build the quality system, validate processes, train teams, and establish the documentation foundation that an inspector will evaluate.
If a new facility is scheduled to open in 2028, that VP Quality search needed to start in early 2026. For many companies expanding right now, it has not.
The same arithmetic applies downstream.
Authorised Users (the nuclear medicine physicians who can legally prescribe therapeutic radiopharmaceuticals) require 700 hours of documented training and supervised experience under NRC regulations. That is not a certification course. It is a structural bottleneck baked into federal regulation.
In the 2025 NRMP Match, just 13 applicants competed for nuclear medicine PGY-2 spots nationwide. The average nuclear medicine physician is approaching 60. The retirement wave will arrive at exactly the moment dozens of alpha-emitting programmes approach commercialisation.
Capital moves at the speed of commercial demand. The workforce moves at the speed of academic training pipelines.
What to do about it
The companies that will staff their sites are doing three things now:
Hiring from adjacent modalities early. Experienced GMP manufacturing leaders from biologics or cell therapy, brought in 24 months before operational need, with runway to learn hot-lab operations, radiation safety, and short half-life logistics alongside existing operators. Hire for the leadership capability. Train for the modality.
Building workforce plans alongside facility plans. Not after. The critical leadership hire made nine months too late is the most expensive delay in any new facility programme. Talent planning and construction planning should run in parallel.
Mapping the market before committing. Understanding the actual available candidate pool in a specific geography before breaking ground changes site selection decisions, compensation structures, and build timelines.
The companies that do this will open operational facilities.
The rest will open buildings they cannot run.
The bottom line
The radiopharma talent crisis of 2028 is not a prediction. It is arithmetic.
SNMMI 2026 gave you the demand signal. Every capacity expansion, every new alpha programme, every pipeline-filling acquisition adds hiring demand to a pool that is not growing at the same rate.
The theranostics certificate and the Regulatory Boot Camp were not routine professional development. They were emergency infrastructure.
If you are planning a radiopharma buildout and have not started the talent mapping, the clock is already running.
That is what we do at ProGen Search. If you want to understand what the candidate market actually looks like before you commit, get in touch.